ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL

BACKGROUND: A randomized phaseII trial on EGFR-amplified recurrent glioblastomas showed that Depatux-M+TMZ improves overall survival compared to the single agent control arms. We performed targeted next-generation-sequencing to identify patients that benefit from the combination. METHODS: DNA and RN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: French, Pim, Kros, Johan, de Heer, Iris, Eoli, Marica, Sepulveda, Juan, Walenkamp, Annemiek, Frenel, Jean-Sebastien, Franceschi, Enrico, Clement, Paul, Weller, Michael, Ansell, Peter, Looman, Jim, Bain, Earle, Morfouace, Marie, Gorlia, Thierry, Golfinopoulos, Vassilis, van den Bent, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216397/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados